ADC Therapeutics S.A. - שווי חברה להכנסות ADCT

לוגו של חברה ציבורית adctherapeutics.com (ADCT)

ADC Therapeutics minimizes risks by developing conjugates to combat solid tumors and hematologic cancers. Robust R&D potential ensures technological superiority, while stable demand for Zynlonta strengthens operating revenues. The EV/Sales valuation allows for filtering out market noise to reveal the business's actual fundamentals, while 1293.27 reflects the current level of the company's enterprise value-to-revenue metric.

ADC Therapeutics S.A. - שווי חברה להכנסות ADCT (תקופה 23.11.2025 - 20.11.2026)

adctherapeutics.com - פילוחים אנליטיים ומדדי מפתח (ADCT)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח ראשוני של החברה:ADC Therapeutics ADCT
דוגמת מוצר של ADC Therapeutics

This indicator determines business value relative to annual revenue, excluding the impact of debt obligations. The EV/Sales valuation ratio trend allows for tracking the market consensus on asset value regardless of capital structure. This metric reacts sharply to quarterly sales reports, capturing monetization efficiency. For ADC Therapeutics (ADCT), this figure reflects the market value of the potential of their targeted blood cancer therapy system. It is critical for investors to compare this value with the adoption rates of innovative conjugates in oncological practice.